{
    "Trade/Device Name(s)": [
        "BD Phoenix Automated Microbiology System - Cefpodoxime 0.125-8 \u03bcg/mL",
        "BD PhoenixM Automated Microbiology System for use with the antimicrobial agent cefpodoxime (0.125-8 \u03bcg/mL) - Gram-negative ID/AST or AST only Phoenix panels"
    ],
    "Submitter Information": "Becton, Dickinson and Company",
    "510(k) Number": "K063300",
    "Predicate Device Reference 510(k) Number(s)": [
        "N50510",
        "K020321",
        "K020323",
        "K020322"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LON"
    ],
    "Summary Letter Date": "October 31, 2006",
    "Summary Letter Received Date": "November 1, 2006",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 866.1645"
    ],
    "Regulation Name(s)": [
        "Fully Automated Short-Term Incubation Cycle Antimicrobial Susceptibility Devices"
    ],
    "Analyte Class(es)": [
        "microbiology"
    ],
    "Analyte(s)": [
        "Cefpodoxime"
    ],
    "Specimen Type(s)": [
        "Pure culture isolates of Gram-negative aerobic and facultative anaerobic bacteria",
        "Enterobacteriaceae",
        "Non-Enterobacteriaceae",
        "Gram-positive bacteria isolates (Staphylococcus, Enterococcus)"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "BD Phoenix instrument"
    ],
    "Method(s)/Technology(ies)": [
        "Broth microdilution",
        "Redox indicator detection",
        "Automated incubation and reading"
    ],
    "Methodologies": [
        "Antimicrobial susceptibility testing",
        "Minimal inhibitory concentration determination"
    ],
    "Submission Type(s)": [
        "Automated system",
        "Analyzer",
        "Panel",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for BD Phoenix Automated Microbiology System using cefpodoxime panels for automated antimicrobial susceptibility testing of Gram-negative and Gram-positive bacteria.",
    "Indications for Use Summary": "Intended for in vitro quantitative determination of antimicrobial susceptibility by minimal inhibitory concentration (MIC) for most Gram-negative aerobic and facultative anaerobic bacteria and Gram-positive bacteria isolates from pure culture, including Enterobacteriaceae, Non-Enterobacteriaceae, Staphylococcus, and Enterococcus, using cefpodoxime in Phoenix panels.",
    "fda_folder": "Microbiology"
}